[Recent progress in development of antibiotics against Gram-negative bacteria]

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Multidrug-resistant (MDR) bacterial infections, particularly Gram-negative pathogens, represent a critical global health threat.
• The pipeline for new antimicrobial agents has been notably stagnant for decades, with few novel antibiotics approved.
• Existing research shows limited success in developing effective treatments for MDR Gram-negative bacteria.

Purpose of the Study:

• To review recent research and development activities focused on combating MDR Gram-negative bacteria.
• To summarize compounds that have advanced to the clinical development stage.
• To explore alternative strategies for developing novel antibacterial agents.

Main Methods:

• Literature review of recent research and development activities.
• Focus on compounds that have entered clinical development.
• Analysis of new analogues of existing antibiotics and novel mechanisms of action.

Main Results:

• Despite challenges, some compounds show promise in vitro, animal models, and clinical studies.
• The overall global antibiotic pipeline remains discouraging.
• Several promising drug candidates face unexpected development hurdles.

Conclusions:

• There is an urgent need for novel therapeutic strategies against MDR Gram-negative bacteria.
• Compounds in clinical development, including new analogues and agents with novel mechanisms, offer potential solutions.
• Continued research and development are crucial to overcome challenges and replenish the antibiotic pipeline.